Manufacturing development and clinical production of NKG2D Chimeric Antigen Receptor-expressing T cells for autologous adoptive cell therapy

BACKGROUND: Adoptive cell therapy employing natural killer group 2D (NKG2D) chimeric antigen receptor (CAR)-modified T cells has demonstrated preclinical efficacy in several model systems, including hematological and solid tumors. We present comprehensive data on manufacturing development and clinic...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Cytotherapy
Main Authors: Murad, Joana M., Baumeister, Susanne H., Werner, Lillian, Daley, Heather, Negre, Helene, Reder, Jake, Sentman, Charles L., Gilham, David, Lehmann, Frederic, Snykers, Sarah, Sentman, Marie-Louise, Wade, Terri, Schmucker, Adam, Fanger, Michael W., Dranoff, Glenn, Ritz, Jerome, Nikiforow, Sarah
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6127861/
https://ncbi.nlm.nih.gov/pubmed/30180944
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jcyt.2018.05.001
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares